Three months after Amgen Inc back-tracked, Canada's Valeant Pharmaceuticals International Inc has decided to buy AstraZeneca Plc's psoriasis drug brodalumab.

The previous deal for the drug was called off by Amgen in view of reports showing suicidal tendencies seen in patients who took the drug. On Tuesday, Valeant announced that it will pay $100 million to AstraZeneca for the deal.

In addition, the company will make payments of up to $170 million and $175 million in milestone payments. The company will make the final requests before the drug regulatory authority of the US, for sale, in the last quarter this year.

The drug, however, will not be allowed to enter the markets in specific countries including Japan and a few in Asia in view of regulatory restrictions.

Brodalumab is a unit of IL-17 inhibitor drugs. It blocks a signaling pathway inside the body which is responsible for elevating inflammatory diseases. Psoriasis is an autoimmune disease wherein the growth rate of skin cells increases to such an extent that it begins to show up as infection.

AstraZeneca, meanwhile, revealed that the deal may not have much effect on its financial position at least for the present year as the sum will only contribute to the company's externalization revenue.

The deal comes as a boon to hundreds of patients suffering from the disease- Psoriasis. AstraZeneca claimed that clinical trials have shown high efficacy of brodalumab in treatment of moderate to severe psoriasis in a considerable number of patients.

"Our agreement will help to bring brodalumab to patients with psoriasis," said Pascal Soriot, chief executive officer of AstraZeneca.